JBIO Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -11.05%, SMA50 5.33%, SMA200 39.85%). The stock’s 14-day RSI is 44.33 (neutral), while the ATR of 1.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.6% below its high and over 106.09% above its low. Average 10-day trading volume of 324.99 thousand shares is slightly above the 3-month average of 283.39 thousand, indicating heightened recent market interest.

Jade Biosciences, Inc. generated EPS of -$11.36 over the past year. Five-year average earnings growth is -77.98%. Wall Street analysts project EPS growth of 70.0% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $28.00 to $14.00. The high target offers 106.95% upside. The low target suggests 3.47% downside. The mean target is $21.17. This offers 56.47% upside. Jade Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -15.79%. The prior quarter beat by 100.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 27, 2025.

Jade Biosciences, Inc. last paid a dividend of 2.4 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $40.82. This means the shares are trading below this model’s fair value.

Jade Biosciences, Inc. (NASDAQ:JBIO) closed at $13.53 USD, gaining $0.28 (2.11%) from the previous close of $13.25. The stock is currently mid-range between its 52-week high and low $6.57 and $100.10. With a market capitalization of about $441.43 million, Jade Biosciences, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.02). Key stats such as the average daily volume over the past year has been around 289.17 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Jade Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tom Frohlich, the company employs approximately 50 people and listed since April 29, 2025. Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases.

Jade Biosciences, Inc. trades at a P/E ratio of -8.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.99 suggesting the stock is closer to book value. The P/FCF stands at -5.76, also above market averages.

Our AI price prediction model suggests that Jade Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.87%, with price expected at $14.73 by January 23, 2026, within a range of $13.11 to $16.45 3-Month Outlook: Projected fall of -18.92%, reaching $10.97 by April 09, 2026, with a range of $10.77 to $11.16. 1-Year Outlook: Projected gain of 75.61%, with price at $23.76 by December 31, 2026, within a range of $23.25 to $24.21.

Jade Biosciences, Inc. (NASDAQ:JBIO) shares are down -14.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Jade Biosciences, Inc. trading at a premium to the broader market with a P/E of -8.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.17, suggesting 56.47% upside. Our AI forecast model points to short-term strength (8.87% over two weeks), a medium-term fall (-18.92% over three months), and a longer-term gain (75.61% over one year), with expected trading ranges indicating moderate volatility.